Amgen Inc.

The provided transcript from Amgen's Q4 2020 earnings call does not explicitly mention any current or upcoming fundraising activities through debt or equity. Key related points include: - Amgen acknowledges that capital continues to flow into the biotech sector with intense competition for assets. - The company emphasizes the importance of efficient capital allocation and execution to maintain leadership. - They highlight a strong track record of internal R&D and selective external investments but do not specify any planned fundraising. - CFO Peter Griffith mentions maintaining flexibility in the operating margin and executing productivity improvements, but no specific capital raise is detailed. - Overall, the focus is on using existing capital efficiently rather than announcing new debt or equity raises at this time. No direct information about new fundraising via debt or equity was provided on page 6 or elsewhere in the transcript.

- Amgen plans to increase R&D investment in 2021, focusing on promising mid-stage pipeline candidates. - Strategic capital allocation continues towards the biosimilars franchise due to strong margins and high-quality execution. - Ongoing investments in digitization and automation to improve productivity and commercial model efficiency. - Building differentiated capabilities in early research, particularly in human genetics and large-scale proteomics to enhance drug target selection and trial design. - Developing induced proximity platform (formerly referred to as targeted protein degradation) to expand the universe of druggable targets through multi-specific activities. - Committed to advancing ESG goals, including carbon neutrality by 2027 and waste reduction, indicating potential strategic investments in sustainability. - Continued global expansion efforts, including promotional investments in key international markets like Japan, China, Russia, and Australia.

- Amgen expects continued volume growth from key products such as Prolia, Otezla, Repatha, and EVENITY alongside innovative oncology portfolio. - Anticipates some uncertainty and variability in revenue and earnings throughout 2021 due to COVID-19 and effects on new patient starts and social distancing. - Biosimilars are a strong growth area, with continued volume expansion though offset by net price declines. - International sales growth expected from expanded market presence in Japan, China, Australia, and emerging markets. - Otezla growth projected globally through new indications (mild to moderate psoriasis) and expanded international launches. - New product launches including sotorasib (KRAS G12C inhibitor) and tezepelumab (severe asthma) will contribute to revenue growth. - Digital transformation in commercial operations aims to improve productivity and sustained engagement post-COVID. - Mid-single digit net price declines globally expected due to industry price pressures. - Overall 2021 revenue guidance: $25.8 billion to $26.6 billion with continued focus on volume-driven growth.

- Amgen expects continued growth in 2021 with revenue guidance between $25.8 billion and $26.6 billion. - Non-GAAP earnings per share (EPS) guidance is $12.12 to $13.17 per share, reflecting 5% non-GAAP EPS growth year-over-year. - Operating expenses expected to grow about 7% in 2021 due to investments in innovation and commercial efforts. - Operating margin projected to be roughly 50% in 2021, supported by an industry-leading cost structure. - Mid-single-digit declines in net selling prices anticipated, reflecting ongoing industry price pressures. - Revenue growth driven by volume increases in products like Prolia, Otezla, Repatha, EVENITY, biosimilars, and innovative oncology portfolio. - The company plans increased R&D investment in 2021 to advance pipeline and support new product launches. - Capital allocation prioritizes internal/external innovation, capital expenditures, and shareholder returns, including dividends and share repurchases.

The provided transcript from the Q4 2020 Amgen earnings call does not explicitly mention details regarding the current or expected orderbook or pending orders. The discussion focuses primarily on: - Product sales growth (9% YoY, 15% volume growth) - Regulatory submissions and approvals (e.g., sotorasib, Tezepelumab) - Pipeline progress (e.g., BiTE programs AMG 160 and AMG 757) - Commercial strategies and global market expansion - Supply and commercial field organization adjustments No specific figures or commentary on backlog, orderbook, or pending orders were disclosed on page 7 or surrounding pages. Therefore, no concrete data is available from this transcript on current or expected orderbook or pending orders.